FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Ceigall India IPO and Emcure Pharma IPO.
Ceigall India IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Emcure Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Ceigall India IPO | Emcure Pharma IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | ICICI Securities Limited Iifl Securities Ltd Jm Financial Limited |
Kotak Mahindra Capital Company Limited Axis Capital Limited J.P. Morgan India Private Limited Jefferies India Private Limited |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Ceigall India IPO is up to ₹1,252.66 Cr whereas the issue size of the Emcure Pharma IPO is up to ₹1,952.03 Cr. The final issue price of Ceigall India IPO is ₹401.00 per share and of Emcure Pharma IPO is ₹1,008.00 per share.
Ceigall India IPO | Emcure Pharma IPO | |
---|---|---|
Face Value | ₹5 per share | ₹10 per share |
Issue Price (Lower) | ₹380.00 per share | ₹960.00 per share |
Issue Price (Upper) | ₹401.00 per share | ₹1,008.00 per share |
Issue Price (Final) | ₹401.00 per share | ₹1,008.00 per share |
Discount (Retail) | ||
Discount (Employee) | ₹38.00 per share | ₹90.00 per share |
Market Lot Size | 37 shares | 14 shares |
Fresh Issue Size | 1,70,63,640 shares | 79,36,507 shares |
Fresh Issue Size (Amount) | up to ₹684.25 Cr | up to ₹800.00 Cr |
OFS Issue Size | 1,41,74,840 shares | 1,14,28,839 shares |
OFS Issue Size (Amount) | up to ₹568.41 Cr | up to ₹1,152.03 Cr |
Issue Size Total | 3,12,38,480 shares | 1,93,65,346 shares |
Issue Size Total (Amount) | up to ₹1,252.66 Cr | up to ₹1,952.03 Cr |
Ceigall India IPO opens on Aug 01, 2024, while Emcure Pharma IPO opens on Jul 03, 2024. The closing date of Ceigall India IPO and Emcure Pharma IPO is Aug 05, 2024, and Jul 05, 2024, respectively.
Ceigall India IPO | Emcure Pharma IPO | |
---|---|---|
Anchor Bid Date | Jul 31, 2024 | Jul 02, 2024 |
Issue Open | Aug 01, 2024 | Jul 03, 2024 |
Issue Close | Aug 05, 2024 | Jul 05, 2024 |
Basis Of Allotment (Tentative) | Aug 06, 2024 | Jul 08, 2024 |
Initiation of Refunds (Tentative) | Aug 07, 2024 | Jul 09, 2024 |
Credit of Share (Tentative) | Aug 07, 2024 | Jul 09, 2024 |
Listing date (Tentative) | Aug 08, 2024 | Jul 10, 2024 |
Anchor Lockin End date 1 | Sep 05, 2024 | Aug 07, 2024 |
Anchor Lockin End date 2 | Nov 04, 2024 | Oct 06, 2024 |
Ceigall India IPO P/E ratio is 20.67, as compared to Emcure Pharma IPO P/E ratio of 34.55.
Ceigall India IPO | Emcure Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Ceigall India Limited Financial Information (Restated Consolidated)Ceigall India Limited's revenue increased by 46.92% and profit after tax (PAT) rose by 81.81% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Emcure Pharmaceuticals Limited Financial Information (Restated Consolidated)Emcure Pharmaceuticals Limited's revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 99.99% | 98.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 82.06% | 78.24% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 20.67 | 34.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹6985.41 Cr. | ₹19029.89 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 33.57%% | 16.90%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 31.98%% | 19.37%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 1.17 | 0.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹19.40 | ₹29.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 33.57%% | 16.87%% |
In the Ceigall India IPO retail investors (RII) are offered 1,09,16,012 shares while in Emcure Pharma IPO retail investors are offered 1,09,16,012 shares. Qualified institutional buyers (QIB) are offered 62,37,721 shares in Ceigall India IPO and 38,53,234 shares in Emcure Pharma IPO.
Ceigall India IPO | Emcure Pharma IPO | |
---|---|---|
Anchor Investor Reserveration | 93,56,581 shares | 57,79,850 shares |
Market Maker Reserveration | ||
QIB | 62,37,721 shares | 38,53,234 shares |
NII | 46,78,291 shares | 28,89,926 shares |
RII | 1,09,16,012 shares | 67,43,160 shares |
Employee | 55,096 shares | 1,08,900 shares |
Others | ||
Total | 2,18,87,120 shares | 1,37,03,538 shares |
Ceigall India IPO subscribed 14.01x in total, whereas Emcure Pharma IPO subscribed 67.87x.
Ceigall India IPO | Emcure Pharma IPO | |
---|---|---|
QIB (times) | 31.26x | 191.24x |
NII (times) | 14.83x | 49.32x |
Big NII (times) | 16.28x | 54.90x |
Small NII (times) | 11.92x | 38.16x |
RII (times) | 3.82x | 7.36x |
Employee (times) | 11.84x | 8.81x |
Other (times) | ||
Total (times) | 14.01x | 67.87x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|